Neurology Medical News about relapsing-remitting multiple sclerosis, glatiramer acetate, interferon beta-1b

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

250 mug or 500 mug interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
The Lancet Neurology, 09/10/09

O'Connor P et al. – 500 mug interferon beta–1b was not more effective than the standard 250 mug dose, and both doses had similar clinical effects to glatiramer acetate. Although interferon beta–1b and glatiramer acetate had different adverse event profiles, the overall tolerability to both drugs was similar.

<< Previous
Endovascular treatment with angioplasty or stenting versus...

Next >>
Evolution of Stroke Diagnosis in the Emergency Room - A...

Serum levels of CXCL13 are elevated in active multiple sclerosis
Multiple Sclerosis, 10/08/09 Relevance Score: 96%

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial : The Lancet
The Lancet - Early Online Publication, 10/08/09 Relevance Score: 90%